C-type natriuretic peptide neuromodulates via "clearance" receptors.
Trachte, George J., S. Kanwal, Barbara J. Elmquist, and Richard J. Ziegler.
Departments of Pharmacology and Medical Microbiology and Immunology,
University of Minnesota-Duluth, School of Medicine, Duluth, MN 55812, (218)
-726-8975, FAX (218)-726-6235
APStracts 2:0031C, 1995.
A recently discovered endogenous autacoid, C-type natriuretic peptide, was
tested in a pheochromocytoma (PC12) cell line for effects on: 1)
catecholamine release induced by a depolarizing stimulus, 2) guanylyl and
adenylyl cyclase activities, and 3) specific 125I-atrial natriuretic peptide
binding. C-type natriuretic peptide suppressed evoked neurotransmitter
release in the absence of guanylyl cyclase activation or adenylyl cyclase
inhibition; however, both a "clearance" (ANP-C) receptor binding agent, cANF,
and pertussis toxin prevented this neuromodulatory effect. The C-type
natriuretic peptide preferentially bound to receptors that also bound cANF.
The results suggest that C-type natriuretic peptide suppressed evoked
neurotransmitter efflux by binding to ANP-C receptors coupled to a pertussis
toxin-sensitive process; furthermore, the neuromodulatory effect of C-type
natriuretic peptide occurred independently of guanylyl cyclase activation or
adenylyl cyclase inhibition. The novel aspects of these findings are: 1)
neuromodulatory effects of C-type natriuretic peptide; 2) guanylyl cyclase
-independent actions of C-type natriuretic peptide; and 3) ANP-C receptors
mediating C-type natriuretic peptide actions.
Received 15 March 1994; accepted in final form 15 November 1994
APS Manuscript Number C0144-4.
Article publication pending Am. J. Physiol. (Cell Physiology).
ISSN 1080-4757 Copyright 1994 The American Physiological Society.
Published in APStracts on 27 February 1995.